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1. IntroductIon
jj Lung transplantation for end-stage CF has been performed for more than two decades. 
jj In very well selected CF patients, lung transplantation provides a net survival benefit and 
an improved quality of life, superior to all other patients with underlying diagnoses other 
than CF.
jj In CF, liver transplantation for end-stage CF-liver disease is performed less frequently. 
jj In rare cases, combined liver-lung transplantation has been carried out in selected CF 
patients successfully. 
jj Experience is very limited with transplantation of the pancreas or pancreatic islets in 
patients with CF-related diabetes.
2. Lung transpLantatIon
2.1. Indications for referral and listing 
jj Mean waiting times on transplantation list have increased over recent years in 
switzerland. currently, the mean waiting time for a blood group a lung transplant 
recipient is approximately 200 days and for a blood group o recipient approxima-
tely 400 days. 
jj In general, recipients with CF are not prioritized on the waiting list unless a recipient is 
younger than 40 years of age, in which case an organ of a donor less than 40 years 
of age is preferentially allocated. Thus, waiting times for CF lung transplant candidates 
are rather similar to patients with COPD, and longer compared to some other countries 
(USA, France). Therefore, early referral of patients with advanced cF-lung disease 
for transplant assessment is vital.
jj In 2014, the Pulmonary Council of the International Society for Heart and Lung Transplanta-
tion (ISHLT) updated the consensus document for the selection of lung transplant candi-
dates including for CF. Details that are given below.
jj In general, lung transplantation should be considered for patients with end-stage CF-lung 
disease meeting all of the following general criteria:
js >50% risk of death due to CF lung disease within 2 years without lung transplantation
js >80% likelihood of surviving at least 3-months post-transplant
js >80% likelihood of 5-year post-transplant survival if graft function is sustained
jj In addition to a survival benefit, another desired goal of lung transplantation is a substantial 
symptomatic benefit and improvement of quality of life.
jj The criteria for referral are summarized in table 1.
18. transplantation
authors: Christian Benden, Valérie McLin, Urs Bürgi, Lars C. Huber, Angela Koutsokera, 
John-David Aubert
2 18. TRANSPLANTATION
table 1: Referral criteria for lung transplantation in CF (adapted from1)
FEV1 ≤ 30% predicted or a patient with advanced disease with a rapidly falling FEV1 despite 
optimal therapy (particularly young female patients, NTM-pulmonary disease*, B. cepacia 
complex infection* and/or diabetes mellitus) 
A 6-minute walk distance <400 m
Development of pulmonary hypertension in the absence of a hypoxic exacerbation 
Clinical decline characterized by increasing frequency of exacerbations associated with any of 
the below:
– An episode of acute respiratory failure requiring non-invasive ventilation
– Increasing antibiotic resistance and poor clinical recovery from exacerbations
– Worsening nutritional status despite supplementation
– Recurrent pneumothorax
– Life threatening hemoptysis despite bronchial embolization
* See section 2.4, Specific considerations
2.2. contraindications 
jj Contraindications (in particular relative contraindications) are often center-specific. These 
issues should be discussed with the transplant center well in advance. Generally, the fol-
lowing applies (table 2).
table 2: Contraindications to lung transplantation in CF (adapted from1)
absolute contraindications
– Recent history of malignancy:
•	 In most cases, a 5-year disease-free interval is required
•	 In cases with a low predicted risk of recurrence after lung transplantation, e.g. non- 
melanoma localized skin cancer that has been treated appropriately, a 2-year di-
sease-free interval may be acceptable.
•	 In cases with a high risk of recurrence, even a 5-year disease-free interval may not be 
sufficient.
–  Untreatable significant dysfunction of another major organ system (i.e. heart, liver, kidney) 
unless combined transplantation is performed
–  Uncorrected atherosclerotic disease with suspected or confirmed end-organ ischemia, 
not amenable to revascularization
– Acute medical instability (e.g. acute sepsis, myocardial infarction, liver failure)
– Uncorrectable bleeding disorder
– Chronic infection with highly virulent and/or resistant microbes, including M. tuberculosis
– Significant chest wall or spinal deformity 
– Class II or III obesity (BMI > 35.0 kg/m2)
– Non-adherence to medical therapy 
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–  Psychiatric or psychological conditions associated with the inability to cooperate with the 
medical/allied health care team and/or adhere with complex medical therapy
– Substance abuse (e.g. alcohol, tobacco, marijuana) within the last 6 months
relative contraindications
– Class I obesity (BMI 30.0 to 34.9 kg/m2)
– Progressive or severe malnutrition
– Severe, symptomatic osteoporosis
– Extensive prior chest surgery with lung resection
–  Mechanical ventilation and/or extracorporeal life support. However, carefully selected 
patients without other acute or chronic organ dysfunction may be successfully bridged to 
transplantation
–  Chronic infection with highly resistant or highly virulent bacteria, fungi, mycobacteria or 
viruses (e.g. chronic extra-pulmonary infection expected to worsen after transplantation, 
including hepatitis B, hepatitis C, and HIV)
–  Other medical conditions that have not resulted in end-stage organ damage, such as 
poorly treated diabetes mellitus, systemic hypertension, important atherosclerotic  
disease, epilepsy, peptic ulcer disease, or poorly controlled gastro-esophageal reflux
2.3. specific considerations
jj non-tuberculous mycobacteria (ntM) (see also chapter “non-tuberculous 
mycobacteria”)
js Patients with NTM disease who are being evaluated for transplantation should have 
the organism confirmed according to microbiology guidelines and commence therapy 
before transplant listing.
js Patients with persistent M. abscessus or M. avium infection despite optimal therapy may 
be referred for consideration of transplantation. Decisions regarding suitability will be 
made on an individual basis according to risk stratification. M. abscessus or M. absces-
sus subsp. massiliense should be identified at a subspecies level by accurate molecular 
methods in a reference laboratory.
js Progressive pulmonary or extra-pulmonary disease due to NTM (despite optimal the-
rapy or due to inability of the patient to tolerate the therapy) is usually a contraindication 
for transplant listing. 
jj Burkholderia cepacia complex (Bcc) (see also chapter “B. cepacia complex”)
js Patients with B. cenocepacia have an increased risk of mortality due to recurrent 
disease after transplantation. 
js Patients with species other than B. cenocepacia do not have an increased risk for mor-
tality after transplantation and can be listed providing other criteria are met.
js At the time of writing, the Zurich Lung Transplant Team considered infection with 
B. cenocepacia an absolute contraindication for lung transplantation. At CURT (Centre 
Universitaire Romand de Transplantation), the inclusion in the waiting list for lung 
transplantation of a CF patient colonized by B. cenocepacia is discussed on a case by 
case basis.
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2.4. pre-transplant evaluation
jj Evaluation for lung transplantation is center-specific, but generally the following applies:
js Outpatient clinic appointments. 
js Contact with lung transplant recipients for “first-hand experience”.
js Inpatient assessment prior to decision for listing.
js Patient education and teaching regarding transplantation (information relative to the 
follow-up while on list and preparation for the post-transplant period).
js table 3 outlines the general evaluation during the pre-transplant assessment.
table 3: Exams that are considered during the pre-transplant assessment 
Extensive laboratory tests including 
– Serology (e.g. for CMV, EBV, HBV, HCV, HIV)
– Blood group 
– HLA typing and anti-HLA antibodies
Microbiology
– Complete sputum culture (bacteriology, fungus, mycobacteria)
– Screening for MRSA
– Urine and stool culture 
– ENT culture (in selected cases)
Vaccination status and completion of vaccination if necessary*
PFTs (spirometry, body plethysmography, diffusion capacity)
6-minute walk test
Blood gas analysis and/or oxymetry and/or capno-oxymetry
Imaging studies
– Chest CT scan (if not performed within the last 6 months)
– Ventilation/perfusion scan
– Abdominal ultrasound (or abdominal CT in selected cases)
– Imaging of the sinuses
– DEXA bone density scan
– Duplex ultrasound of central venous access
ECG
Echocardiography (right heart catheter in selected cases) 
Coronary angiography in patients >50 years of age
Colonoscopy for patients >40 years of age 
Gastroscopy and colonoscopy for patients >50 years of age
(continued)
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Diverse specialized reviews by:
– Thoracic surgeon
– Anesthesiologist
– Infectious diseases specialist
– Psychiatrist
– Nutritionist
– Dentist 
– Gynecologist 
– ENT Specialist (in selected cases)
– Opthalmologist (in selected cases) 
– Social worker 
*see also chapter “Vaccination”
2.5. post-transplant outcomes and main complications
jj In very well selected cF patients, lung transplantation provides a net survival be-
nefit and an improved quality of life.
js According to the 2017 ISHLT Registry Report, the median survival of adult CF patients 
receiving lung transplantation is 9.2 years, which is superior to the survival of LT patients 
with other diagnoses and also to the survival of transplanted pediatric CF patients (5.2 
years).
js Some clinical prediction tools have been developed to estimate the risk of mortality be-
fore or after lung transplantation in CF. Although these scores may provide information 
on patient risk stratification, scores have important limitations and cannot incorporate all 
the components of the multidisciplinary assessment of the individual transplant candi-
date. Currently, these scores are not widely used in clinical practice.
jj cF does not recur in the transplanted lungs, however, patients may develop other 
pulmonary complications the frequency of which depends on the time-point after 
transplantation:
js primary graft dysfunction may develop during the immediate post-operative period
js infectious complications and acute cellular rejections are more frequent during the first 
months after transplantation, whereas 
js chronic lung allograft dysfunction (CLAD) is the main cause of long-term mortality and 
develops in approximately 50% of the patients within 5-years of follow-up. The severity 
and clinical course of CLAD varies and in cases of important lung function deterioration 
re-transplantation may be considered.
jj Lung transplantation does not address extra-pulmonary CF manifestations, some of which 
may complicate the clinical course after lung transplantation (e.g. DIOS during the periope-
rative period, diabetes etc.), whereas new comorbidities may develop over-time as a result 
of the immunosuppressive treatment (table 4).
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 table 4:  Examples of long-term medical complications after lung transplantation 
in CF
system complication Main contributing factors
Gastrointestinal Gastroesophageal reflux 
Gastroparesis
It is common before transplantation in CF but the 
frequency increases further after transplantation. 
Possibly due to surgery-induced vagal nerve and 
esophageal dysfunction
Renal Renal dysfunction Calcineurin inhibitors
Diabetes
Hypertension
Endocrine Diabetes mellitus Corticosteroids
Calcineurin inhibitors
mTOR inhibitors
Osteoporosis Corticosteroids
Calcineurin inhibitors (cyclosporine, possibly 
tacrolimus)
Cardiovascular Hypertension Calcineurin inhibitors
Corticosteroids to a less extent
Dyslipidemia Corticosteroids
Calcineurin inhibitors (cyclosporine, to a less 
extend tacrolimus)
mTOR inhibitors
Malignancy PTLD
Skin
Digestive, other
Epstein-Barr virus (EBV) for PTLD
Sun exposure for skin cancer
Immunosuppression for all types of cancer
EBV: Epstein-Barr virus, mTOR: mammalian target-of-rapamycin, PTLD: post-transplant lymphoproliferative disease
3. LIVer transpLantatIon
3.1. Indications
jj Seven per cent of CF patients, mostly children and young adults, develop multi-lobular 
biliary cirrhosis and may need liver transplantation (see also chapter “Hepatobiliary 
diseases” ).
jj A score used for referral to liver transplant assessment is presented in table 5. This score 
has been used mostly in children with CF liver disease and does not include lung function 
parameters.
jj In practice, other indices, such as declining lung function, poor nutritional status or 
presence of encephalopathy are also considered. Patients with an FEV1 <60% of 
predicted value, are most likely to benefit from liver transplantation.  
jj Indications for liver transplantation in CF are summarized in table 6. 
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  table 5:  Score indicating the need for liver transplant assessment, NB score 
(adapted from3)
Indication score 
Portal hypertension Splenomegaly must be present
– Varices present 4
Score  
only one
– Bleed with 1-2 transfusions 8
–  Variceal bleed >twice or a single life 
threatening bleed
10
Ascites 6
Hepatocellular function Albumin <30 g/l 2
PT>19 sec 2
Hypersplenism WBC<4 G/L 2
PLT<100.000/μL 2
Nutrition BMI<16th percentile 6
Mid-arm circumference <5th percentile 6
NB: score>10 indicates the need for liver transplant assessment.
In practice, other parameters are also considered:
1) declining lung function  
2) poor nutritional status
3) encephalopathy
 table 6: Indications for liver transplantation in CF (adapted from4)
Progressive hepatic dysfunction 
   – declining serum albumin (<30 g/l)
   – increasing coagulopathy not corrected by vitamin K
Development of ascites and jaundice
Intractable variceal bleeding, not controlled by conventional treatment
Hepatopulmonary syndrome and portopulmonary hypertension
Severe malnutrition, unresponsive to intensive nutritional support
Deteriorating quality of life related to liver disease
Deteriorating pulmonary function
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3.2. contraindications
jj Contraindications (in particular relative contraindications) are often center-specific. 
These issues should be discussed with the transplant center well in advance. Generally, 
the following applies (table 7).
 table 7:  Absolute contraindications for liver transplantation in CF  
(adapted from5)
–  Severe multi-organ dysfunction unless multi-organ transplantation can be considered
–  Malignancy (non-hepatobiliary) or metastatic hepatobiliary malignancy
– Active alcohol/substance abuse
– Uncontrolled sepsis
–  Psychiatric or psychological conditions associated with the inability to cooperate with the 
medical/allied health care team and/or adhere with complex medical therapy
Note: prior abdominal surgery or surgery for portal hypertension should be considered during risk assessment
3.3. specific considerations
jj Pulmonary and nutritional status should be optimized before liver transplantation.
jj Peri-operative antibiotics should be adapted to microbiology results and continually 
re-assessed while the patient is on the waiting list.
jj Biliary-enteric anastomosis is prefered to end-to-end choledochal anastomosis owing to 
the presence of abnormal epithelium in the recipient bile duct.
jj A portosystemic shunt may be considered to delay liver transplantation in patients with 
well-preserved synthetic liver function but the benefits of delaying liver transplantation 
must be weighted against the potential risks of portosystemic shunting (encephalopathy, 
 hepatopulmonary syndrome, portopulmonary hypertension).
3.4. pre-transplant evaluation
jj A system-based pre-transplant evaluation, similar to the one performed for lung 
transplantation is used for liver transplant candidates. 
jj In addition to the exams described in table 4, the following are performed for patients 
assessed for liver transplantation: 
js Serology for HEV
js Abdominal angio CT scan
js Head MRI (evaluation for signs of encephalopathy)
js Specialized reviews by:
 – liver transplant surgeon
 – neurologist 
 – neuropsychologist (in selected cases to assess for minimal hepatic encephalopathy)
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3.5. post-transplant outcomes and main complications 
jj Post liver transplant life expectancy is greater in patients younger than 18 years of age than 
older adults.
jj Although based on older data, analysis of the European liver transplant registry (ELTR) and 
Scientific registry of transplant recipients (SRTR) showed a 3 and 5-year patient survival 
of approximately 80%. It is possible that with improved current management, survival may 
also have improved. 
jj In regard to the impact of liver transplantation on other outcomes
js Lung function: in one study CF patients having received isolated liver transplant impro-
ved their FEV1 by 5.9%.
js Comorbidities:  increased prevalence of diabetes mellitus. For other comorbidities in-
duced by immunosuppresion see table 5.
js Nutritional status: a slight improvement of nutritional status has been reported.
jj In very well selected CF patients, liver transplantation provides a net survival benefit and an 
improved quality of life. Although post liver transplant survival in adult CF patients has been 
shown to be less compared to adults having a liver transplant for other indications, this 
discrepancy was not related to graft failure but most likely to the presence of comorbidities. 
4. coMBIned LIVer-Lung transpLantatIon (cLL-tx)
4.1. Indications
jj Patients with severe lung disease and liver cirrhosis are at high risk for mortality and mor-
bidity after lung transplantation due to liver failure. For these patients combined liver-lung 
transplantation (CLL-Tx) is usually warranted. 
jj Although not stated clearly in the literature, it is generally accepted that CLL-Tx is indicated 
when the chance of survival with a single organ transplantation is estimated <50%.
jj Patients <18 years old have better survival rates than adults. Thus in severe two-system di-
sease, combined transplant should be considered during adolescence or early adulthood.
4.2. pre-transplant evaluation
jj Evaluation for liver and lung transplant as mentioned above. 
jj Additionally:
js Pulmonary changes associated with portal hypertension are an important consideration. 
Transplanting the lung in the presence of porto-systemic shunting secondary to portal hy-
pertension could impair graft function or compromise clinical outcomes due to hypoxemia.
js Careful anesthesia planning is essential to determine which lung will be transplanted 
first and to plan circulatory bypass. 
js Ascertaining the extent of vascular access or compromise is essential.  
js Adequate nutrition is essential in the pretransplant period to ensure that the patient is 
anabolic at the time of transplant. Total parenteral nutrition (TPN) may be required as 
enteral nutrition is often poorly tolerated in advanced portal hypertension.
jj A detailed pre-, peri-, and post- transplant protocol is essential. 
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4.3. outcomes
jj Unfortunately, data on outcomes are scarce.
jj In a study of the UNOS database, looking at 11 patients, survival of CLL-Tx was equal to 
isolated liver or isolated double lung transplantation. 
jj In a more recent study examining older adults with CLL-Tx due to various diagnoses (not 
CF only), 30-day, 90-day, and 1 year survival was 87.5%, 75.0% and 71.4% respectively. 
jj Subsequent studies have confirmed these findings and suggested that younger patients 
fare slightly better. 
5. transpLantatIon oF tHe pancreas or pancreatIc IsLets 
jj transplantation of the pancreas 
js Currently, data are very limited concerning pancreas transplantation in CF: a recent 
analysis of the United Network for Organ Sharing (UNOS) database showed that among 
the 4600 CF patients transplanted between 1987 and 2014, only 28 received a pancreas 
transplant (in most cases combined with liver transplants).
js The procedure is underused because it is not considered life-saving and, in cases of 
combined transplantation, it increases the complexity of the operation and the probabi-
lity of complications.
jj transplantation of pancreatic islets
js It is a less invasive option than pancreatic transplantation. It consists of the isolation and 
culture of donor pancreatic islet cells and their transplantation by catheterization of the 
portal vein or the transverse colic vein. Elevation of plasma C-peptide is measured as 
an indicator of islet allograft recovery.
js There are no studies on the long-term efficacy and safety of this procedure in CF.
js Only case reports for simultaneous or sequential lung - pancreatic islet transplantation 
in cases of brittle diabetes (poor glycemic control with numerous hypoglycemic epi-
sodes) in an attempt to improve glucose stability, decrease insulin requirements and 
eliminate hypoglycemic events.
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